Four Developers that Will Expand the Use of FLT3 Inhibitors in the AML Market

At the 2017 American Society of Hematology (ASH) conference, fms-like tyrosine kinase (FLT3) inhibitors were one of the key classes of targeted therapies showing encouraging clinical results in acute myeloid leukemia (AML) patients.

admin January 4, 2018

Each bubble represents a different industrial sponsor. Bubble size represents the number of Phase I–III clinical trials for that sponsor. The analysis includes all trial status and geography. Credit: GlobalData.

Based on the analysis of company sponsors currently running clinical trials with FLT3 inhibitors, four companies are clearly leading their development: Novartis, Astellas, Daiichi, and Arog, with 19, 14, 10, and nine Phase I–III trials, respectively.

While Novartis’ Rydapt (midostaurin) is now approved both in the US and EU, GlobalData forecasts FLT3 inhibitors with higher target specificity, such as Astellas’ quizartinib, Daiichi’s gilteritinib, and Arog’s crenolanib, to be widely adopted across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan).

Rydapt won the first US approval in the first-line setting; however, due to the small patient pool targeted in this setting (less than 8% of all AML patients), GlobalData forecasts the sales of the highly specific FLT3 inhibitors, gilteritinib and quizartinib, to exceed Rydapt’s sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Therefore, major clinical and commercial opportunities remain for FLT3 inhibitors, and GlobalData anticipates fierce competition among the four leading developers will arise in early 2019.